Bahija JallalChief Executive Officer at Immunocore
Dr. Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.
Prior to taking the helm at Immunocore in January 2019, Bahija was President of MedImmune, the global biologics research and development unit of AstraZeneca. She was also Executive Vice President of AstraZeneca and was a member of its senior executive team reporting to the CEO. Dr. Jallal joined MedImmune in March 2006. Under her leadership, MedImmune/AstraZeneca developed and launched five new biologic medicines in three therapeutic areas.
Dr. Jallal serves on the Boards of Anthem, Inc. and Guardant Health. She is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation.
Dr. Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a member of the Women in Cancer Research Council of the American Association of Cancer Research; and the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine. She is the past President of the Association of Women in Science. Dr. Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.